ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1555

Quality of Life of Rheumatoid Arthritis Patients Treated with Biologics

Sonia Tropé1, Gérard Thibaud2, Françoise Alliot3, Didier Formont4 and Sadek Krouri5, 1149 avenue du Maine, ANDAR, Paris, France, 2ANDAR patient organisation, Paris, France, 3AFLAR, Paris, France, 4A+A Healthcare Market Research, BOULOGNE, France, 5Public affair & Advocacy Rheumatology, Sanofi, Gentilly, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: quality of life and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Treatments Poster II – ARHP

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Major advances in the management of rheumatoid arthritis (RA) have been recorded over the last decade thanks to the introduction of biologics. However, medical needs concerning functioning and quality of life of patients are not completely fulfilled(1). In France, the quality of life of RA patients treated with long-term biotherapy in real life has never been the subject of a specific study.

Methods: In partnership with two patients’ associations, a cross-sectional observational survey of RA patients treated with biologics since at least one year, with the aim of assessing their functioning (using the HAQ-DI(2) questionnaire) and quality of life (EQ-5D(3) questionnaire) on a daily basis was carried out. Treatment satisfaction and expectations have been also evaluated.

Results: A total of 504 RA patients have been included in the study (mean age = 62.4 years; 18% male and 82% female). The average RA duration was 19.2 years and the mean treatment period with biologics was 8 years. About 40% of patients received first-line biologic treatment and 30% received 2nd– or 3rd-line biologic treatment. When RA was poorly controlled with first-line treatment, patients changed their treatment every 3 years on average. Reasons for switching biologics included poor efficacy (60% of patients) and tolerance problems (31%). Hospitalization due to RA progression during the last 12 months were reported by 22% of patients in 1st line-treatment and by 32% of patients in 2nd line and more. Functional disability, particularly affecting manual activities of daily living, also increased with the number of treatment lines. In addition, more than 50% of the patients in professional activity had to adapt or change their activity because of their state of health. Regarding health perception, only 14% of patients were satisfied with their symptom improvement (scored 80 to 100 on a scale from 0 to 100). The average score was 63.5 (quite satisfying). In addition, whether on symptoms or well-being, only a third of patients were satisfied with their condition. If patients recognize the major contribution of biologics (average satisfaction score was 7.5/10), they are more than 80% to expect the arrival of new biologics to improve their quality of life.

Conclusion: Despite the major therapeutic progress achieved with biologics for the management of rheumatoid arthritis, the results of this survey conducted with patient associations demonstrate a persistent functional disability in patients with RA as well as a reduced quality of life. The level of expectation of these patients remains high concerning future therapeutic alternatives.

  1. Gerhold et al. Rheumatology (Oxford). 2015, 54:1858-66.
  2. Guillemin et al. Rev Rhum Mal Osteoartic. 1991, 58:459–65.
  3. Perneger et al. Value Health. 2010, 13:631-5

Disclosure: S. Tropé, Nordic Pharma, 6; G. Thibaud, Pfizer, Inc., 6,MSD, 6,Sanofi, 6,UCB, Inc., 6; F. Alliot, XXX, 6; D. Formont, X, 3, 5; S. Krouri, SANOFI, 3.

To cite this abstract in AMA style:

Tropé S, Thibaud G, Alliot F, Formont D, Krouri S. Quality of Life of Rheumatoid Arthritis Patients Treated with Biologics [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/quality-of-life-of-rheumatoid-arthritis-patients-treated-with-biologics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quality-of-life-of-rheumatoid-arthritis-patients-treated-with-biologics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology